Acknowledgements
This study was funded by Janssen-Cilag AB. Additional research funding was provided by the following foundations: The Swedish Cancer Society, The Cancer Society in Stockholm, King Gustav V Jubilee Fund, The Cancer and Allergy Foundation, StratCan Karolinska Institutet, AFA Insurance, The Stockholm County Council, The Swedish Society of Medicine, Blodcancerfonden and Dr Åke Olsson Foundation. We thank Ms Leila Relander for secretarial assistance, Peter Gray, Nicholas Rusbridge of PAREXEL Access Consulting and Dusha Jeyakumaran of Janssen EMEA for editorial support.
Presented in part at the Annual Meeting of the American Society of Hematology, Orlando, FL, Dec 5-8, 2015.
Potential conflict of interest
Anders Österborg and Lotta Hansson have received research grant support and honoraria for scientific lectures from Janssen. Johanna Repits, Frans Søltoft , Joris Diels are previous or present employees at Janssen-Cilag. The other authors declared no conflict of interest. Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1246727.